Loading...
XNASANIX
Market cap83mUSD
Dec 24, Last price  
2.58USD
1D
0.00%
1Q
-18.10%
Jan 2017
-52.22%
Name

Anixa Biosciences Inc

Chart & Performance

D1W1MN
XNAS:ANIX chart
P/E
—
P/S
395.35
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
11.94%
Rev. gr., 5y
-28.36%
Revenues
210k
-99.99%
494,462439,785508,651486,8522,063,1231,055,797730,6751,003,193940,010388,8503,667,3209,255,000300,000362,5001,112,500250,0000512,5002,469,000,000210,000
Net income
-10m
L-27.28%
-3,360,655-4,451,257-7,600,901-5,458,218-5,821,604-16,489,015-5,175,131-7,378,036-4,252,799-10,080,086-9,606,314-1,379,043-5,016,428-5,008,991-13,996,025-11,994,451-10,132,516-12,946,631-13,491,000-9,811,000
CFO
-6m
L-4.36%
-1,205,122-1,720,332-1,847,108-2,396,859-901,868-2,501,566-2,405,817-716,000-3,140,748-3,186,798-2,379,2611,363,367-3,381,699-3,796,710-4,273,400-4,741,426-6,175,671-4,936,881-6,492,000-6,209,000
Earnings
Jan 21, 2025

Profile

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
URL
https://www.anixa.com/
IPO date
Oct 07, 1983
Employees
4
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑102022‑102021‑102020‑102019‑102018‑102017‑102016‑102015‑10
Income
Revenues
210
-99.99%
2,469,000
481,656.10%
Cost of revenue
11,221
13,917
Unusual Expense (Income)
NOPBT
(11,011)
2,455,083
NOPBT Margin
99.44%
Operating Taxes
(280)
Tax Rate
NOPAT
(11,011)
2,455,363
Net income
(9,811)
-27.28%
(13,491)
4.20%
Dividends
Dividend yield
Proceeds from repurchase of equity
92
97
BB yield
-0.09%
-0.06%
Debt
Debt current
52
46
Long-term debt
298
396
Deferred revenue
Other long-term liabilities
Net debt
(23,494)
(29,245)
Cash flow
Cash from operating activities
(6,209)
(6,492)
CAPEX
Cash from investing activities
(5,602)
(10,728)
Cash from financing activities
366
452
FCF
(10,965)
2,461,049
Balance
Cash
23,844
29,687
Long term investments
Excess cash
23,834
Stockholders' equity
(228,851)
(218,923)
Invested Capital
252,397
247,344
ROIC
1,007.27%
ROCE
8,638.27%
EV
Common stock shares outstanding
30,980
30,374
Price
3.16
-43.57%
5.60
17.40%
Market cap
97,897
-42.45%
170,094
24.77%
EV
73,437
140,002
EBITDA
(10,965)
2,455,125
EV/EBITDA
0.06
Interest
104
Interest/NOPBT
0.00%